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Cells have the capacity to convert mechanical stimuli into chemical changes.This process is
based on the tensegrity principle, a mechanism of tensional integrity.To date, this principle
has been demonstrated to act in physiological processes such as mechanotransduction
and mechanosensing at different scales (from cell sensing through integrins to molecu-
lar mechanical interventions or even localized massage). The process involves intra- and
extracellular components, including the participation of extracellular matrix (ECM) and
microtubules that act as compression structures, and actin filaments which act as ten-
sion structures.The nucleus itself has its own tensegrity system which is implicated in cell
proliferation, differentiation, and apoptosis. Despite present advances, only the tip of the
iceberg has so far been uncovered regarding the role of ECM compounds in influencing
biotensegrity in pathological processes. Groups of cells, together with the surrounding
ground substance, are subject to different and specific forces that certainly influence bio-
logical processes. In this paper, we review the current knowledge on the role of ECM
elements in determining biotensegrity in malignant processes and describe their implica-
tion in therapeutic response, resistance to chemo- and radiotherapy, and subsequent tumor
progression. Original data based on the study of neuroblastic tumors will be provided.
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INTRODUCTION
The study of spatial and temporal responses to mechanical forces
of tissue structures of biological organisms is a growing field in
health sciences. Such responses can be modified by mechanother-
apeutic interventions, ranging from the molecular level to whole
body systems, and involving a broad spectrum of target molecules
belonging to the microenvironment. In order to carry out mechan-
otherapy effectively, we should consider the stabilizing elements of
tension and compression, or biotensegrity systems, existing at all
structural levels in the body. Tensegrity is an architectural princi-
ple put forth by Buckminster Fuller in the 1960s (1, 2). According
to the tensegrity principle, structures or tensegrity systems are
stabilized by continuous tension with discontinuous compression
(3). Coming under the term biotensegrity, the tensegrity princi-
ple applies to essentially all detectable scales in the body, from the
musculoskeletal system to proteins or DNA (4, 5).
In this review, we highlight the current challenges and on-going
issues for dissecting the mechanisms of tumor extracellular matrix
(ECM) biotensegrity and discuss how these concepts may be trans-
lated into treatment and prognosis of cancer. To illustrate the
biotensegrity principle, we present some preliminary results on the
mathematical integration of multimodal data, combining imag-
ing and non-imaging tumor tissue data, acquired in the context
of neuroblastoma (NB) studies, suggesting testable hypotheses for
making prognostic predictions and therapeutic response related
with this principle.
CELL AND TISSUE BIOTENSEGRAL PHYSIOLOGY
Several studies have demonstrated that cells can function as inde-
pendent pre-stressed tensegrity structures through their cytoskele-
ton architecture. Ingber defined the pre-stressed tensegrity model
as a structural support on biological systems. It is constituted by
a number of continuous elements of tension and a number of
discontinuous elements resistant to compression providing a stabi-
lized structure (6–14). As a tensegrity network,a single cell presents
such continuous tension (mediated by cytoskeleton elements such
as microfilaments and intermediate filaments) and local discon-
tinuous compression (mediated by ECM and other cytoskeleton
elements such as microtubules). The individual pre-stressed cells
are poised and ready to receive mechanical signals and convert
them into biochemical changes (15). Therefore, cell membrane,
nucleus, and all the organelles are hard-wired by the cytoskeletal
scaffold. When the mechanical cue is received, sensed mainly by
focal adhesion complexes induced by integrins, the signal modifies
the cytoskeletal scaffold. Thus, the local mechanical signal is ampli-
fied and propagated through a series of force-dependent biochem-
ical reactions, whereby intra-cellular signaling pathways become
sequentially activated through mechanotransduction (16). At the
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molecular level, several elements resist compression, such as all
structures containing alpha-helix, beta-sheet, or even DNA back-
bone structures, while others, such as attraction and repulsion
forces of molecular, atomic, and ionic bonds (such asVan der Waals
forces, covalent bonds, etc.), resist continuous tension. Many mol-
ecules display such structures and are subject to these two forces
at different stages along the mechanical intra-cellular signal path-
ways. Among these abundant and intermingled pathways, many
remain unknown. We believe that knowledge on how we could
potentially interfere with these signaling pathways or cascades may
provide new therapeutic targets. Nevertheless, as many molecules
play multiple roles in different pathways, molecular therapy based
on mechanotransduction, should be carried out on specific targets
to avoid adverse effects.
The tensegrity architecture of the cytoskeleton and signal path-
ways is linked to the tensegrity elements of the outer and inner
nuclear membrane through KASH–SUN bridges, where KASH
proteins are located in the outer nuclear membrane (Nesprin-1
and Nesprin-2 link nuclei with actin filaments, Nesprin-3 interacts
with intermediate filaments,and Nesprin-4 binds to microtubules)
(17–19) and SUN proteins in the inner nuclear membrane (Samp1
and lamin). This connection is critical for intra-cellular force
transmission in physiological homeostasis (20–22) and might
ensure that chromatin organization is not perturbed when tis-
sues experience stress, and may be fundamental for normal
development (23).
The self-balanced mechanical stability of the cytoskeleton
enables the macro-mechanical forces to be converted into molec-
ular changes. Since cells are connected to each other through cell
junctions, mediated mainly by cadherins, these changes not only
affect the cell that receives the signal, but are also transferred to the
neighboring cells. Indeed, recent biophysical studies have revealed
that the size of cell–cell contacts can be regulated in response to
the mechanical forces exerted on those junctions and that cells are
also able to regulate the forces exerted on their junctions (24–26).
It is known that cell–cell junctions are anchored to neighbor-
ing cells and focal adhesions to ECM, and all are connected to
the intra-cellular cytoskeletal network, therefore the forces that
cross these structures fluctuate strongly when tissue is remodeled.
It is becoming apparent that these structures do not just trans-
mit forces while maintaining tissue cohesion, but also respond to
fluctuations in force by actively influencing cell morphology and
behavior (27). The biological significance of this mechanotrans-
duction is to promote coordinated cytoskeletal reorganizations
that can define changes in shape across the whole tissue. The basal
lamina plays a central role in this process. It provides physical
support to epithelial cells, surrounds muscle cells, fat cells, and
Schwann cells, and is the environment where cells and ECM bind
through focal adhesions and integrins. Accordingly, the shape of
tissue cells (round or flattened) and the three-dimensional struc-
ture of the tissue patterns that constitute glands, alveoli, ducts, and
papillae (among others), depend on the stiffness and flexibility and
on the coordinated movement of the basal lamina (28).
ROLE OF ECM IN BIOTENSEGRITY
During the last decade, cell-matrix contacts based on the trans-
membrane adhesion receptors from the integrin family or focal
adhesions have emerged as the major mechanosensitive struc-
tural elements that connect, collect, process, and integrate the
information of the ECM. Recent proteomic studies have not
only found many more components, but also have revealed that
many of these elements are recruited to focal adhesions in a
force-dependent manner, supporting the view that focal adhesions
harbor a network of mechanosensitive processes (29). Integrins
are transmembrane αβ heterodimer receptors that function as
structural and functional bridges between the cytoskeleton and
ECM molecules. Specifically, α8β1 or tensegrin can bind to sev-
eral ECM molecules and has been shown to be associated with
focal adhesion points, where it participates in the regulation of
spreading, adhesion, growth, and survival in different neuronal
and mesenchymal-derived cell types (30, 31).
Various interconnected cells bind to their microenvironment,
forming a mechanical tensegral system, which implies the exis-
tence of a mechanical balance between compression (ECM) and
tension (cell) forces. The ECM is made up of a mixture of ground
substance [glycosaminoglycans (GAGs) – mostly hyaluronan, pro-
teoglycans, and glycoproteins] situated in close relationship with
a fibrous scaffold [reticulin (Ret F) – elastin and collagen fibers
(Col F)], and supplies much of the structural support available to
parenchymal cells in tissues, by adding tensile strength and flexibil-
ity (32). The ECM is a dynamic and multifunctional regulator and
has its own biotensegrity with Ret F and elastin fibers acting as ten-
sional elements, and ground substance and Col F as compression-
resistance elements. This tensegral network is considered to be a
solid-state regulatory system of all cell functions, responsible for
changes in genes and proteins, as well as alterations in cell shape
and movement (33–35). One result of cell–ECM biotensegrity is
substrate rigidity, which can control nuclear function and hence
cell function (36). Cells can use this substrate rigidity to exert
traction forces, thus altering the ECM. Indeed, in a state of rec-
iprocal isometric mechanical tension, a dynamic balance exists
between cell traction forces and points of resistance within the
ECM. This dynamic biotensegral system with its mechanotrans-
duction phases (Figure 1) enables our cells to mechanosense,
modifying their microenvironment, thus promoting ECM remod-
eling in homeostasis and in tissue disorders (37). Manipulation of
this mechanical balance could be used to promote tissue regen-
eration. In fact, various studies have demonstrated that different
elasticities of the ECM drive mesenchymal stem cell differentiation
in a very specific way. Neurogenic, myogenic, or osteogenic differ-
entiations are induced under identical matrix serum conditions,
with variations in ECM softness, strength, and stiffness (38). Fur-
thermore, ECM stiffness guides cell migration. It has been shown
that fibroblasts prefer rigid substrates and when placed on flexible
sheets of polyacrylamide, they migrate from the soft to the stiff
areas (39). Under homeostatic conditions, collagen fibrils have
a minimal turnover. However, this turnover is accelerated dur-
ing tissue remodeling and tumor development, as evidenced by
the serum levels of its degradation products (40). Studies of the
ECM have revealed that the components of the tumor microen-
vironment are fundamental, not only for the regulation of tumor
progression (41, 42), but also are essential even before the tumor
appears. The stromal cells are able to transform the adjacent cells
through an alteration in the homeostatic regulation of the tissue,
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FIGURE 1 | Mechanotransduction phases. (A) When forces are exerted on
a tissue after proliferation of tumor and stroma cells, a cell within the cell
mass (for example, the one marked in green) is subject to mechanical
deformation in a phase called mechanocoupling. Following the principle of
tensegrity at the tissue level, ECM elements apply compression forces to the
tissue cells and tissue cells exert tension forces between themselves and to
the ECM. Biotensegral elements of the boxed area are detailed in (B–D).
(B) This particular tumor cell activates a biochemical coupling phase in which
the mechanical signal is transformed into intra-cellular biochemical signals
through the integrin–cytoskeleton–nuclear matrix structure or
stretch-activated cation channels within the cell membrane, among other
mechanisms. Some essential players in mechanosensing are shown (44–47).
(C) The biochemical signal is transmitted to neighbor cells (marked in purple)
through cell–cell junctions. Following the principle of tensegrity at the cell
level, the compression elements are the microtubules, whereas the tension
elements are the intermediate filaments and the actin filaments.
(D) A fibroblast neighbor cell can produce a stiff ECM which in turn enables
the first cell to flatten and migrate through this stiffened ECM. The effector
cell response phase arises from the biotensegrity principle: a simple
cytoskeleton when the ECM compression is low switches to a complex
cytoskeleton when the ECM exerts high compression on the cells and the
cells exert high tension on the ECM.
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including the control of architecture, adhesion, cell death, and
proliferation (43).
CELL AND TISSUE BIOTENSEGRITY IN CANCER
Cancer can be understood as a disease of the developmental
processes that govern how cells organize into tissues (48). The
tumor microenvironment is comprised of a variety of cell types
lying among a network of various ECM fibers merged within the
interstitial fluid and gradients of several chemical compounds,
which constantly interplay with malignant cells (34). Therefore,
we can infer that the previously described biotensegral systems
also exist within tumor tissue. In fact, the dynamic mechanical
balance achieved through mechanosensors, cytoskeletal tensegrity,
molecular biotensegral intra-cellular pathways, ECM with com-
pressive and resistant elements, supportive cells (such as fibroblasts
and multiple tumor-associated immune cells), and vascular and
lymphatic vessels tensional structures, can be as important as the
genetic instability of tumor cells in the pathogenesis and evolution
of the malignant process (42, 49). In this regard, various studies
have demonstrated the importance of cell–ECM biotensegrity in
cancer (34, 48, 50). Indeed, a desmoplastic reaction is frequent in
many solid tumors, such as breast,prostate, colon,or lung, in which
high levels of TGF-b and PDGF are found. These growth factors
are produced by the mesenchymal cells of the tumor stroma and
induce immunophenotypic changes. These changes are observable
by studying actin-alpha, myosin, vimentin, desmin, and the altered
production of several ECM proteins, such as collagens, laminin,
tenascin, ECM metalloproteinases (MMP), and MMP-inhibitors
(43). Additionally, ECM stiffness modulates cancer progression;
cancer cells promote stiffening of their environment, which in
turn feeds back to increase malignant behaviors such as loss of
tissue architecture and invasion (51). For instance, the speed of
malignant cells in vitro is affected by the geometry of the ECM.
Human glioma cells move faster through narrow channels than
through wide channels or in non-stretched 2D surfaces. This is
thought to be triggered by an increase in the polarity of the trac-
tion forces between cell and ECM (52). Indeed, recent publications
describe that not only neoplastic ECM stiffness, but also the firm-
ness of tumor cells play a significant role in tumor progression.
The firmness of tumor cells, especially the metastatic cells, has
been found to be lower than that of the normal cells of the same
sample, and is caused by the loss of actin filaments and/or micro-
tubules and the subsequent lower density of scaffold (53, 54). In
this regard, it has been shown that the transformation from a
benign proliferative cell into a malignant cell can be produced by
a peculiar phenotypic change, known as epithelial–mesenchymal
transition (55). This transformation involves breaking contact
with sister cells and increasing motility, as a result of a change in
the epithelial cytoskeleton, with its corresponding proprieties for
a pseudomesenchymal phenotype, which enables migration, inva-
sion, and dissemination (56). While normal cells adhere to their
environment through integrins, and their body has a proper con-
sistency, tumor cells lose that consistency and tensegrity, becoming
easily deformable elements (causing pleomorphism), with high
elasticity (enhancing infiltration) and with an increased degree of
mobility (enabling metastasis) (57). In breast cancer, the genomic
profile expressing mainly mesenchymal features is actually found
in the most invasive cell lines (58). Moreover, it has been published
that chronic growth stimulation, ECM remodeling, alteration of
cell mechanics, and disruption of tissue architecture are non-
genetic influences on cancer progression (42, 49). These ideas
not only agree with basic predictions of cellular tensegrity, but
also support the idea that therapy based on the manipulation of
the biotensegrity principle cues should be considered as a way to
revert the malignant phenotype (59, 60).
In cancer research, the hallmark which includes the physical
aspects of tissue has been less investigated, but it is known that
this hallmark is one of the most basic mechanisms in enhancing
tumor proliferation and creating resistance to cancer treatment,
among other processes (61). A previous study by our group
takes in account some structural elements of ECM that have
the capacity to influence physical conditions and suggests that
Schwannian stroma cells are not the only important factor in the
histopathologic analysis of neuroblastic tumors (50). Specifically,
multi-parametric analysis of other tumor stroma components
(Ret F, Col F, GAG, and immune cells) detected by classic his-
tochemistry (HC) and immunohistochemistry (IHC) techniques
and incorporated into a quantitative morphological analysis would
improve the value of the International NB Pathology Classifica-
tion (62). As we will show later, chemotherapy and radiotherapy
are known to act on tumor cells as well as on stromal cells and
ECM elements (63, 64). As a consequence, injury to the ECM can
contribute directly to treatment resistance, creating niches of resis-
tant tumor cells (64, 65). Furthermore, damage to DNA induces
the production of cytokines and growth factors by stromal cells,
this triggers inflammation, cell survival, and tumor progression,
thus the effect of therapy on ECM may be to promote relapse or
chemoresistance (66, 67). We hypothesize that studying the dif-
ferent elements of the ECM, as one of the main contributors to
biotensegrity, through objective morphometric analysis and the
creation of mathematical networks of histologic sections stained
with HC and IHC, can shed light on how biotensegrity influences
tumor microenvironment and could provide clues to its action
mechanism.
EVIDENCES OF ECM BIOTENSEGRITY CHANGES IN
MALIGNANT TISSUE
It is known that tumor cells alter the mechanical properties of
the microenvironment in order to create favorable conditions for
their proliferation and/or dissemination (68). In addition, adhe-
sion molecules such as E-cadherin are involved in the processes of
tissue differentiation and morphogenesis and play an important
role in modulating the invasiveness of tumor cells in breast cancer
and other epithelial tumors (69). For instance, the reciprocal com-
munication between the stromal cells and the tissue parenchyma
directs gene expression, and in prostate carcinoma and breast car-
cinoma, the oncogenic potentiality arises from stroma-associated
fibroblasts, immune response, and the alterations of biotenseg-
rity (49, 70). Deregulation and disorganization of the composi-
tion, structure, and stiffness of the ECM elements progressively
increase interstitial fluid pressure, leading to limited penetration
and dissemination of therapeutic agents within solid tumors, thus
enabling the creation of niches within tissues and organs that
offer sanctuary to tumors and activate therapy resistance programs
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(11–13, 64, 65). Tumor cells are not the only cells that change the
mechanical properties of the microenvironment. Despite all the
efforts of tumor cells to make ECM elements work for their sur-
vival and proliferation, tumor stromal cells, specifically, immune
system cells, try to reverse the pathological condition. Indeed,
two lymphoproliferative syndromes (follicular lymphoma and
Hodgkin lymphoma) are good examples of the fact that a tumor
can be considered as functional tissue, connected and dependent
on the microenvironment, which sends and receives signals to and
from the tumor tissue itself. In such syndromes, tumor microen-
vironment stromal cells, including immune response, determine
the morphology, clinical stratification, aggressiveness, prognosis,
and response to treatment of the tumor (71).
In the next two sub-sections, we describe the methods devel-
oped for the study of biotensegrity in neuroblastic tumors.
MORPHOMETRIC ANALYSIS OF ECM ELEMENTS – AN EXAMPLE IN NB
Accurate quantification of pathology specimens using imaging
technology to analyze the variations in structural tissue that arise
from interactions between tumor and stroma cells and ECM ele-
ments is providing important information. This approach would
allow biotensegral patterns to be included in computational for-
mulations for risk stratification systems and aid in designing better
anti-cancer treatment strategies (29). However, the validity of
the model depends on the quality of the data. This quantifi-
cation depends on the staining, scanning, image analysis, and
statistical evaluation. For that purpose, automatic stained sections
must be digitized using microscopic preparation scanners such as
Aperio Scanscope XT (Aperio technologies) or Panoramic Midi
(3Dhistech) or with a photomicroscope if a scanner is not avail-
able. Different image analysis systems can be used, such as Image
Pro-plus software (Media cybernetics), ImageScope (Aperio tech-
nologies),Panoramic viewer (3D Histech), free software (ImageJ of
the NIH), or self-designed software to obtain customized macros
or algorithms (informatic protocols) to detect and characterize
the quantity (number of objects and area occupied), size (area,
width, length), shape (aspect, roundness, perimeter ratio, frac-
tal dimension), and orientation (angle), among other parameters,
of the ECM elements of interest. All systems provide mark-up
images or masks, which represent the recognized and measured
element in white upon a black background. The use of tissue
microarrays is advised for standardization purpose of background
subtraction and color segmentation, given that these techniques
tend to be dependent of the intensity of the staining and algo-
rithms must be recalibrated with every change of intensity/ground
noise/contrast staining, thus losing objectiveness. Further details
regarding objective quantification of different cell and ECM ele-
ments and a flowchart of the analysis used by our group, are
described elsewhere (50).
Neuroblastic cells are known to be committed in a complex
interaction with the surrounding tumor microenvironment and
we believe that patients with neuroblastic tumors, specifically those
still subject to therapeutic failure despite current knowledge, could
benefit from novel therapeutic strategies which could originate
from the study of ECM biotensegrity. To investigate such new
therapeutic targets, we have objectively quantified Ret F, Col I
F, GAGs (Gomori, Masson’s trichrome, and Alcian blue pH 2.5
HC, respectively), blood vessels (CD31 IHC, Dako), lymph vessels
(D2-40 IHC, Dako), and cell markers, including leukocyte lin-
eage (CD45/LC IHC, Dako) and NB cells, in primary NB. A first
approach to the evaluation of the role of ECM biotensegrity in neu-
roblastic tumors is the observation of the mark-up images of tissue
microarrays cylinders comprising a mixture of tumor and normal
tissue either in the primary and/or metastatic location. In the par-
ticular case presented in Figure 2, included for illustrative purpose,
a clear disruption in the organization of the ECM elements can be
observed when passing from the normal tissue area to the neoplas-
tic tissue. In the tumor area, Ret F becomes disorganized, Col I F
is slightly increased (although minimal), GAGs almost disappear,
CD45 reactive cells accumulate, and blood vessels vary in size and
characteristics.
Statistical analysis of the quantitative data of fibers, GAGs,
tumor cells, and immune system markers compared with the
current parameters used to predict risk of relapse (stage, age,
histopathology, state of MYCN oncogene, state of 11q region,
overall genomic profile, and ploidy) (72–74) and other genetic
markers of prognostic interest in a subset of 78 primary neu-
roblastic tumors has already been published by our group, and
highlights the interest of studying ECM in neuroblastic tumors
(50). The fact that ECM elements differ depending on the char-
acteristics of the tumors and, more interestingly, the fact that the
characteristics of ECM elements are related to prognosis (relapse
or overall survival) advocates on behalf of the regulatory role of
ECM biotensegrity in tumor progression.
DEVELOPMENT OF MATHEMATICAL TOPOLOGY OF ECM
ELEMENTS – AN EXAMPLE IN NB
The combination of multidisciplinary efforts by clinicians, biol-
ogists, pathologist, bioengineers, and biostatisticians could eluci-
date how ECM elements interact with tumor and stromal cells. In
this respect, a new and interesting approach is to analyze biopsies
by converting the tissue into a mathematical network of cell-to-cell
contacts (75–78). Using graph theory concepts, these networks can
provide organizational information that seems relevant in embry-
ologic development and disease. For example, this method has
been applied to the analysis of neuromuscular diseases, serving
as a diagnostic tool able to quantify the severity of the pathology
in a muscle biopsy (77). We propose that this technology can be
adapted to the analysis of tumor biopsies. It is already possible to
compare different mark-up images obtained from the analysis of
several markers which have been assessed on serial thin sections
with preserved histology. These overlapping images enable sev-
eral markers to be considered at the same time and allow the
co-location and study of the interaction between continuous ten-
sional elements and discontinuous compression elements. In this
regard, we have analyzed the relationship between different biopsy
components taking the cell nuclei as a reference. The procedure
is based in the identification of the cell nuclei and the calcula-
tion of their respective centroids. These centroids serve as seeds
to perform a Voronoi diagram of Voronoi cells (79, 80). A new
partitioned image is produced in which each nuclei is associated
with its corresponding Voronoi cell. In this way, it is possible to
construct a network based on the neighboring Voronoi cells. Topo-
logical approaches and the use of Voronoi cells need to be able
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FIGURE 2 |Tissue microarray cylinders representing an adrenal
gland infiltration by a poorly differentiated neuroblastoma.
Hematoxylin and eosin staining of (A) adrenal gland and (A’) tumor
tissue. (B–F) Several histochemical and immunohistochemical
stainings of extracellular matrix elements and (B’–F’) their
corresponding mark-up images after image analysis are shown. The
cylinder tissue was stained with (B) Gomori for Ret F, (C) Masson’s
trichrome for Col I F, and (D) Alcian blue pH 2.5 for GAGs; and
immunostained with (E) anti-CD45 for leukocyte-common antigen and
(F) anti-CD31 for Blood vessels. Tumors tend to disrupt the topology of
the ECM of the organ in which they settle, producing changes in
biotensegrity. AG, antigen.
to capture the presence and relative disposition of tissue hetero-
geneities derived from, for example, the luminal space of glands,
blood and lymph vessels, or larger extracellular spaces. They will
be reflected through different characteristics and will be taken into
account for the study, testing if they can be part of the relevant fea-
tures that define a specific condition. The selection of regions of
interest in each biopsy will allow studying only tumor tissue areas
without artifacts that could bias the study, leading to wrong con-
clusions. The combination of graph-related parameters with the
morphometric information will enable a comprehensive analysis
of the changes arising from different compression forces in rela-
tion to the different types of ECM (stiff/soft, organized/chaotic)
in combination with the tumor stroma cells such as immune cell
infiltrates. We have performed preliminary comparisons based
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FIGURE 3 | Network construction from a NB biopsy image. (A) Gomori
staining to visualize Ret F and nuclei from the NB biopsy. (B) Combination
of nuclei (green) and Ret F mark-up images obtained from (A). The white
circumference represents the region of interest processed in (C). (C) Each
nucleus (green) is taken as a seed to build a Voronoi diagram (red) of
Voronoi cells. This allows the creation of a network of cell-to-cell contacts
(black lines) that can be used to extract topological characteristics of the
tissue.
on the genetic features of NB using Ret F and blood vessels (in
addition to the nuclei) as the reference features for providing the
biological clues. This procedure has shown some hints of dis-
crimination regarding the organization and co-location of these
elements (Figure 3). We found that some network characteristics
were relevant to perform this initial separation. This suggests that
diverse backgrounds can respond differently to the pathological
process depending on the organization of the tumor. Following
the same approach, we will use other mark-up images of the posi-
tive cells stained with the different monoclonal antibodies against
the different cells of the leukocyte lineage. We hope that this com-
bination of mathematical and statistical methods will answer the
question on the relationships between ECM biotensegrity and the
changes mediated by the cell infiltrate.
EFFECT OF TREATMENT ON TUMOR MICROENVIRONMENT
AND CONSEQUENCES
There is much evidence that the lack of total specificity of can-
cer therapeutic agents (chemotherapy and radiotherapy) causes
collateral damage to the mechanical properties of the tumor
ECM and benign stromal cells (which were previously fighting
the tumor), creating resistance to therapy and favoring relapse
and metastasis. This fact becomes evident while analyzing post-
treatment biopsies, which contain a high degree of fibrosis and
calcification. Some studies have shown that cancer therapy can
sometimes damage tumor DNA and stromal cells, which results in
the secretion of a spectrum of proteins, including the Wnt fam-
ily members. For example, in prostate cancer, the expression of
this proteins in the tumor microenvironment, regulated by lymph
B cells, attenuates the effects of cytotoxic chemotherapy in vivo,
promoting tumor cell survival and disease progression (63, 81).
It has also been reported that in follicular lymphoma and dif-
fuse large cell lymphoma, treatment with lenalidomide affects
the immune synapses of intra-tumoral T lymphocytes (82). In
breast cancer, treatment with doxorubicin results in an increase in
fibuline-1, an ECM protein, and its binding proteins, fibronectin
and laminin-1, which constitute a source of chemoresistance (83)
and triggers overexpression of maspin protein, which induces the
accumulation of collagen fibers, thus causing disease progression
(84). A novel Toll receptor-9-dependent mechanism that initiates
tumor regrowth after local radiotherapy has also been reported
(85). Monoclonal antibodies against fibulin-1 are able to reverse
such chemoresistance, and the inhibition of MMP seems to have
a therapeutic effect (86).
An example of the effect of treatment in NB is shown in
Figure 4. When comparing a primary NB with its non-primary
sample, we can appreciate that Ret F, GAGs, and Col I F accu-
mulate in the ECM of the post-treatment sample. The amount
of blood macrovasculature is slightly decreased. All these findings
describe a stiffer ECM after multimodal treatment.
POTENTIALITY OF MECHANOTHERAPY
The changes exerted on ECM by therapeutic agents and the per-
spective of the epithelial–mesenchymal transition in epithelial
tumors have opened the door to a new line of treatment, which
considers the genetic and epigenetic mechanisms associated with
resistance to chemotherapy (59, 87). There is a need to personalize
therapeutics taking into account not only the features known to
have prognosis impact, but also new markers, such as the mechan-
ical stress of the tumor ECM elements. Indeed, because of its
importance to the tumor, the ECM represents an “Achilles heel”
that can be exploited in designing cancer therapy. The bionet-
work between the ECM and tumor cells is dynamic, and for every
action, such as exposure to genotoxic stress, there are reactions
and consequences throughout the micro and macrosystem (65).
Removal of ECM barriers will either have a direct negative effect on
tumor cells or facilitate anti-tumor immune responses and drug
treatment, through better intra-tumoral penetration and acces-
sibility to target cells. In this regard, a number of experimental
approaches are aimed toward the transient degradation or down
regulation of ECM proteins using injection of ECM-degrading
enzymes into the tumor or their intra-tumoral expression after
viral- or stem cell-based gene transfer (65). Other approaches
attempt to indirectly decrease tumor-associated ECM by killing
tumor stromal cells that produce ECM proteins (64) or aim
at enhancing the host immune response (88). The potentiality
of therapeutic agents to modify ECM can be turned around in
such a way that new chemicals can be applied to modify a given
ECM stiffness or composition into one shown to trigger a better
prognosis.
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FIGURE 4 | Changes in the ECM after treatment in one neuroblastic
tumor. Several stainings (HC and IHC) of (A–E) a primary neuroblastoma and
(A’–E’) its post-treatment biopsy are shown. The presented mark-up images
of (B,B’) Ret F, (C,C’) Col I F, and (D,D’) GAGs show that these ECM elements
are increased in NPNB. Regarding blood vessels (E,E’), the amount of does
not seem to change after treatment but the type of vessels has changed in
such a way that they are smaller in NPNB. The remodeling characteristics of
the ECM components, with different mechanical properties, are differentially
related to prognostically significant clinical and biological features in NB. The
percentages of stained area are indicated. PNB, primary neuroblastoma;
NPNB, non-primary neuroblastoma (after treatment); HE, hematoxylin and
eosin.
CONCLUDING REMARKS
Biotensegrity is the structural principle of mechanotherapy. Cells
are linked both to each other and to the ECM forming a mechan-
ical biotensegral system in homeostasis. Cell–cell junctions are
anchored to neighboring cells and focal adhesions to ECM, allow-
ing forces to cross via intra-cellular cytoskeletal and nuclear net-
works. These structures fluctuate, and the multiple responses
appear to strongly affect tissue remodeling and cell transfor-
mation. As described, normal organs tissue, primary NB, and
post-treatment NB have a different amount and topography of
biotensegral ECM elements. Conventional approaches have tra-
ditionally focused on the neoplastic cell. Moreover, an arsenal of
mechanotherapeutic approaches to enhance the efficacy of more
classical cancer therapeutics and overcome treatment resistance
has already been discovered. To achieve more effective person-
alized strategies, further studies should consider to improve the
definition of the interactions between tumor and stromal cells and
the ECM elements and vascular constituents of the tumor, as well
as their influence on treatment. We propose that integrating the
tumor topo-functional networks of the ECM elements with the
clinical, histopathology, and genetic information could provide
new information about the impact of biotensegrity on patient
care. Understanding the mechanical properties of tumor ECM
components, related to variations in quantity, degree of interfer-
ence, and types of organization, is key to defining new potential
mechanotherapeutic targets and agents.
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